Your browser doesn't support javascript.
loading
Preserved SARS-CoV-2 neutralizing IgG activity of in-house manufactured COVID-19 convalescent plasma.
Inada, Makoto; Togano, Tomiteru; Terada, Mari; Shiratori, Katsuyuki; Tsuzuki, Shinya; Takamatsu, Yuki; Saito, Sho; Hangaishi, Akira; Morioka, Shinichiro; Kutsuna, Satoshi; Maeda, Kenji; Mitsuya, Hiroaki; Ohmagari, Norio.
Afiliação
  • Inada M; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: minada@hosp.ncgm.go.jp.
  • Togano T; Department of Hematology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: ttogano@hosp.ncgm.go.jp.
  • Terada M; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan; Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: materada@hosp.ncgm.go.jp.
  • Shiratori K; Department of Clinical Laboratory, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: kshiratori@hosp.ncgm.go.jp.
  • Tsuzuki S; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: stsuzuki@hosp.ncgm.go.jp.
  • Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: ytakamatsu@ri.ncgm.go.jp.
  • Saito S; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: ssaito@hosp.ncgm.go.jp.
  • Hangaishi A; Department of Hematology, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: ahangaishi@hosp.ncgm.go.jp.
  • Morioka S; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: shmorioka@hosp.ncgm.go.jp.
  • Kutsuna S; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan; Department of Infection Control, Graduate School of Medicine, Osaka University, 2-15 Yamadagaoka, Suita City, Osaka, Japan. Electronic address: kutsuna@hp-infect.med.osaka
  • Maeda K; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan; Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, Kagos
  • Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: hmitsuya@hosp.ncgm.go.jp.
  • Ohmagari N; Disease Prevention and Control Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo, Japan. Electronic address: nohmagari@hosp.ncgm.go.jp.
Transfus Apher Sci ; 62(3): 103638, 2023 Jun.
Article em En | MEDLINE | ID: mdl-36610860
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article